U.S. Online Retail and Ecommerce Stock News

NYSE:URI
NYSE:URITrade Distributors

Should United Rentals’ Q1 Beat, Guidance Hike and Vanguard Stake Shift URI Investors’ Expectations?

United Rentals reported past first-quarter 2026 results showing sales of US$3,419 million, revenue of US$3,985 million, and net income of US$531 million, alongside a quarterly dividend of US$1.97 per share and a modest increase to its full-year revenue guidance to US$16.9–17.4 billion. Management pointed to strong demand from large construction and infrastructure projects and growth in its specialty rental segment as key drivers behind the earnings beat and guidance raise, while Vanguard...
NYSE:EPAM
NYSE:EPAMIT

Do EPAM Systems’ New Google Cloud Awards Mark a Durable Edge in AI Transformation? (EPAM)

EPAM Systems recently received two 2026 Google Cloud Partner of the Year awards, recognizing its work in AI-driven sustainability solutions and complex database migration projects in EMEA using Google Cloud’s Database Migration Service. This recognition underlines EPAM’s growing role as a technical collaborator for Google Cloud, potentially reinforcing its position in high-value cloud and AI transformation work with enterprise clients. Next, we’ll examine how this Google Cloud recognition...
NasdaqGS:CCEC
NasdaqGS:CCECShipping

Is Capital Clean Energy Carriers (CCEC) Pricing Its Clean Energy Shipping Story Correctly?

If you are wondering whether Capital Clean Energy Carriers at around US$20.61 is a bargain or already pricing in its story, you will want to understand how its current price lines up with different valuation checks. The stock has returned 4.0% over the last week, 9.9% over the last month, 1.0% year to date and 7.3% over the last year. This gives you some context around how sentiment has been shifting. Recent coverage has focused on Capital Clean Energy Carriers as part of broader discussions...
NYSE:GME
NYSE:GMESpecialty Retail

Is It Time To Reassess GameStop (GME) After Its Recent Share Price Swings?

Wondering whether GameStop at around US$26.53 is a bargain, fairly priced, or still riding on hype? This breakdown is designed to help you weigh what the current share price might be reflecting. The stock has seen short term moves, with returns of 6.3% over the last 7 days, 13.6% over the last 30 days, 28.7% year to date, and a 2.3% decline over the last year. The 3 year return sits at 31.4% and the 5 year return at a 33.4% decline. These swings continue to be shaped by recurring attention...
NasdaqGS:STRL
NasdaqGS:STRLConstruction

Is It Too Late To Consider Sterling Infrastructure (STRL) After 220% One Year Surge?

If you are wondering whether Sterling Infrastructure at US$532.67 is priced for perfection or still offers value, this article walks through the numbers in plain English. The stock has delivered returns of 7.1% over the last 7 days, 27.9% over 30 days, 66.9% year to date and 221.6% over 1 year, with a very large 3 year and 5 year gain that is well above 7x. Recent coverage has focused on Sterling Infrastructure's role in capital goods and construction projects across the US, as investors...
NasdaqGS:SANM
NasdaqGS:SANMElectronic

A Look At Sanmina (SANM) Valuation After Earnings Beat Guidance Raise And ZT Systems Momentum

Sanmina (SANM) just reported quarterly results that came in ahead of analyst expectations for both revenue and earnings, supported by demand from the ZT Systems business and core operations, and accompanied by higher full-year guidance. See our latest analysis for Sanmina. The strong earnings beat, higher guidance and fresh US$600m buyback authorization have been reflected in a sharp 71.5% 1 month share price return and a very large 1 year total shareholder return of 178.3%, pointing to...
NasdaqGS:AMRX
NasdaqGS:AMRXPharmaceuticals

How CREXONT’s Positive Phase 4 Data and Reaffirmed Outlook Could Shape Amneal Pharmaceuticals (AMRX) Investors

In April 2026, Amneal Pharmaceuticals reported positive interim Phase 4 ELEVATE-PD data showing CREXONT delivered improved “Good On” time, reduced “Off” time and better motor control for Parkinson’s patients, while reaffirming its full-year 2026 revenue outlook at US$3.05 billion to US$3.15 billion. These results support Amneal’s push into higher-value specialty neurology treatments, potentially enhancing the role of CREXONT within its broader branded portfolio. Next, we’ll examine how...
NYSE:LLY
NYSE:LLYPharmaceuticals

Eli Lilly (LLY) Valuation Check As GLP 1 Growth And Foundayo Approval Lift Guidance

Eli Lilly (LLY) has jumped back into the spotlight after its first quarter 2026 report, as strong GLP‑1 demand and fresh FDA approvals led management to lift full year revenue and profit guidance. See our latest analysis for Eli Lilly. The share price reaction around the earnings beat and guidance raise has been positive in the very near term, with a 1 day share price return of 3.07% and 7 day share price return of 8.98%. However, the 90 day share price return of 7.74% and year to date share...
NasdaqGM:ALVO
NasdaqGM:ALVOBiotechs

Will Alvotech's (ALVO) Legal Transition and Executive Move to Reykjavik Quietly Reframe Its Governance Story?

In recent months, Alvotech announced that longtime General Counsel Tanya Zharov will step down after six years, with a multi‑month transition as incoming executive Lisa Graver assumes expanded leadership responsibilities and several senior leaders relocate to Reykjavik. This combination of legal leadership change and management team relocation could influence how Alvotech manages regulatory risk, governance, and future corporate decision‑making. We’ll now examine how Graver’s expanded...
NasdaqGS:STGW
NasdaqGS:STGWMedia

A Look At Stagwell (STGW) Valuation After Recent Share Price Momentum And Earnings Expectations

Stagwell (STGW) has attracted fresh attention after recent returns and financial figures highlighted its performance in the marketing and digital transformation space. This provides investors with an updated snapshot of growth, profitability, and current market pricing. See our latest analysis for Stagwell. Stagwell’s share price has held at US$6.36 after a mixed short term pattern, with a 1 day share price return of 1.44% and a 7 day share price return showing a 7.15% decline, while the year...
NasdaqGS:AXON
NasdaqGS:AXONAerospace & Defense

Is It Time To Reassess Axon Enterprise (AXON) After Recent Share Price Pullback?

Investors may be wondering whether Axon Enterprise is attractively priced at around US$402 per share, or if the recent excitement has already been accounted for in the stock price. The share price recently closed at US$402.31, with a 1.3% gain over 7 days, a 2.5% decline over 30 days, and returns of a 28.6% decline year to date and a 36.0% decline over 1 year, set against longer term gains of 82.9% over 3 years and 198.6% over 5 years. These mixed returns have put valuation questions back on...
NYSE:ZBH
NYSE:ZBHMedical Equipment

Zimmer Biomet (ZBH) Is Down 9.2% After Strong Q1, CFO Exit And Ongoing Buybacks – Has The Bull Case Changed?

In late April 2026, Zimmer Biomet Holdings reported first-quarter 2026 results showing sales of US$2,086.7 million and net income of US$238.1 million, reaffirmed its full-year revenue growth guidance, detailed ongoing share repurchases totaling US$1.48 billion since 2024, and announced the departure of its CFO, with the Controller and Chief Accounting Officer appointed as interim CFO. The combination of stronger earnings, benefits from technology platforms and tariffs, continued buybacks,...
NasdaqGS:PCRX
NasdaqGS:PCRXPharmaceuticals

How Pacira’s Q1 2026 Results, EXPAREL Data and Proxy Battle May Impact Pacira BioSciences (PCRX) Investors

Pacira BioSciences, Inc. recently reported first-quarter 2026 results showing revenue of US$177.38 million, up from US$168.92 million a year earlier, while net income eased to US$2.92 million and diluted EPS to US$0.07. Alongside these results, the company highlighted real-world Medicare data for EXPAREL showing reduced opioid use and medical costs after outpatient hip replacements, while an activist proxy battle with DOMA Perpetual Capital Management adds a governance twist ahead of the...
NasdaqGS:CDW
NasdaqGS:CDWElectronic

Will CDW’s (CDW) New Strategy Chief Subtly Recast Its AI and Cloud Transformation Story?

CDW Corporation recently announced that Hang Tan joined the company on April 27, 2026, as Chief Strategy and Transformation Officer, reporting to Chair and Chief Executive Officer Christine A. Leahy and overseeing enterprise strategy, the transformation office, and corporate development. Tan’s background in reshaping technology businesses, including prior leadership roles in hybrid cloud and as-a-service models, introduces a fresh dimension to how CDW may approach its long-term strategy and...
NasdaqGS:EQIX
NasdaqGS:EQIXSpecialized REITs

Equinix Expands Nordic Footprint And Satellite Links As Valuation Draws Focus

Equinix (NasdaqGS:EQIX) has agreed to acquire Nordic data center operator atNorth, expanding its presence and capacity in the region. The company announced a new partnership with SpinLaunch to host globally distributed teleports in Equinix data centers. The SpinLaunch partnership is expected to support the Meridian Space satellite constellation for worldwide data connectivity. For investors tracking digital infrastructure, Equinix sits at the intersection of data centers, cloud...
NYSE:TKR
NYSE:TKRMachinery

Timken Belts Sale To Gates Refocuses Business And Attracts Investors

Timken (NYSE:TKR) agreed to sell its belts business to Gates Industrial in a transaction expected to close in the third quarter. The deal is intended to sharpen Timken’s focus on core operations and support margin improvement in its Industrial Motion segment. Transaction proceeds are planned to fund Timken’s broader capital allocation priorities. For you as an investor, this move sits at the intersection of two industrial names that both operate across power transmission and motion control...
NasdaqGS:ISRG
NasdaqGS:ISRGMedical Equipment

Is Intuitive Surgical (ISRG) Pricing Too High After Recent Share Price Weakness

For investors considering whether Intuitive Surgical at around US$457.78 is a fair deal, expensive, or potentially mispriced, this article walks through key clues in the valuation story. The stock has seen mixed recent returns, with a 5.1% decline over the last 7 days, a 1.3% gain over the last 30 days, and year to date and 1 year returns of 18.5% and 13.5% declines, while the 3 and 5 year returns sit at 50.2% and 60.2% respectively. Recent coverage has continued to focus on Intuitive...
NasdaqGS:ACHC
NasdaqGS:ACHCHealthcare

Is It Time To Reconsider Acadia Healthcare Company (ACHC) After This Year’s Strong Rally?

Wondering if Acadia Healthcare Company at around US$27.85 is a bargain or a value trap? This article walks through what the current price might be implying. The stock has returned 1.7% over the past week, 16.2% over the last month, 94.9% year to date and 19.5% over the past year, while the 3 year and 5 year returns of 59.7% and 56.5% declines show that longer term holders have had a very different experience. Recent coverage has focused on Acadia Healthcare Company as a specialist in...